Taken together, our findings demonstrate that mutant p53-regulated YTHDF2 and YTHDF2-mediated m6A mRNA degradation play a critical role in glioma development and could serve as potentially targetable vulnerability. This evidence concerns the gene TP53 and central nervous system cancer.